87 related articles for article (PubMed ID: 18350459)
21. Psychological distress and prostate specific antigen levels in men with and without prostate cancer.
Turner EL; Lane JA; Metcalfe C; Down L; Donovan JL; Hamdy F; Neal D; Vedhara K
Brain Behav Immun; 2009 Nov; 23(8):1073-8. PubMed ID: 19486654
[TBL] [Abstract][Full Text] [Related]
22. Quality of life in patients with skeletal metastases of prostate cancer and status prior to start of endocrine therapy: results from the Scandinavian Prostate Cancer Group Study 5.
Jønler M; Nielsen OS; Groenvold M; Hedlund PO; Damber L; Hedelin H; Waldén M;
Scand J Urol Nephrol; 2005; 39(1):42-8. PubMed ID: 15764270
[TBL] [Abstract][Full Text] [Related]
23. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
[TBL] [Abstract][Full Text] [Related]
24. Fear of cancer recurrence in patients undergoing definitive treatment for prostate cancer: results from CaPSURE.
Mehta SS; Lubeck D; Pasta DJ; Litwin MS
J Urol; 2003 Nov; 170(5):1931-3. PubMed ID: 14532810
[TBL] [Abstract][Full Text] [Related]
25. A 3-y prospective study of health-related and disease-specific quality of life in patients with nonmetastatic prostate cancer treated with radical prostatectomy or external beam radiotherapy.
Yoshimura K; Arai Y; Ichioka K; Matsui Y; Ogura K; Terai A
Prostate Cancer Prostatic Dis; 2004; 7(2):144-51. PubMed ID: 15111981
[TBL] [Abstract][Full Text] [Related]
26. Regret in men treated for localized prostate cancer.
Hu JC; Kwan L; Saigal CS; Litwin MS
J Urol; 2003 Jun; 169(6):2279-83. PubMed ID: 12771770
[TBL] [Abstract][Full Text] [Related]
27. Effects of transurethral resection of prostate on the quality of life of patients with benign prostatic hyperplasia.
O'Sullivan M; Murphy C; Deasy C; Iohom G; Kiely EA; Shorten G
J Am Coll Surg; 2004 Mar; 198(3):394-403. PubMed ID: 14992742
[TBL] [Abstract][Full Text] [Related]
28. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).
Srinualnad S; Charoenkraikamol C; Toraksa S; Uiprasertkul M; Amornvesukit T; Taweemonkongsap T; Udompunturak S; Nualyong C; Tantiwong A
J Med Assoc Thai; 2006 Jan; 89(1):37-42. PubMed ID: 16583579
[TBL] [Abstract][Full Text] [Related]
29. Effects of socioeconomic factors and cancer survivors' worries on their quality of life (QOL) in Japan.
Kobayashi K; Morita S; Shimonagayoshi M; Kobayashi M; Fujiki Y; Uchida Y; Yamaguchi K
Psychooncology; 2008 Jun; 17(6):606-11. PubMed ID: 17972358
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant hormone therapy and external-beam radiation for localized high-risk prostate cancer: the importance of PSA nadir before radiation.
Ludgate CM; Bishop DC; Pai H; Eldridge B; Lim J; Berthelet E; Blood P; Piercy GB; Steinhoff G
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1309-15. PubMed ID: 16029786
[TBL] [Abstract][Full Text] [Related]
31. Improved biochemical disease-free survival of men younger than 60 years with prostate cancer treated with high dose conformal external beam radiotherapy.
Zelefsky MJ; Marion C; Fuks Z; Leibel SA
J Urol; 2003 Nov; 170(5):1828-32. PubMed ID: 14532785
[TBL] [Abstract][Full Text] [Related]
32. Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer.
Punglia RS; Cullen J; McLeod DG; Chen Y; D'Amico AV
Cancer; 2007 Nov; 110(9):1973-8. PubMed ID: 17886252
[TBL] [Abstract][Full Text] [Related]
33. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
34. Targeted-cryosurgical ablation of the prostate with androgen deprivation therapy: quality of life in high-risk prostate cancer patients.
Kang SH; Kim JW; Bae JH; Park HS; Moon DG; Yoon DK; Cheon J; Kim JJ
Asian J Androl; 2006 Sep; 8(5):629-36. PubMed ID: 16847531
[TBL] [Abstract][Full Text] [Related]
35. Information satisfaction in breast and prostate cancer patients: implications for quality of life.
Davies NJ; Kinman G; Thomas RJ; Bailey T
Psychooncology; 2008 Oct; 17(10):1048-52. PubMed ID: 18203242
[TBL] [Abstract][Full Text] [Related]
36. Cancer-related pain and quality of life in prostate cancer patients: assessment using the Functional Assessment of Prostate Cancer Therapy.
Fujimura T; Takahashi S; Kume H; Takeuchi T; ; Kitamura T; Homma Y
Int J Urol; 2009 May; 16(5):522-5. PubMed ID: 19383037
[TBL] [Abstract][Full Text] [Related]
37. Quality of life, health outcomes, and identity for patients with prostate cancer in five different treatment groups.
Galbraith ME; Ramirez JM; Pedro LW
Oncol Nurs Forum; 2001 Apr; 28(3):551-60. PubMed ID: 11338762
[TBL] [Abstract][Full Text] [Related]
38. Factors affecting quality of life in a multiracial sample of older persons with schizophrenia.
Bankole AO; Cohen CI; Vahia I; Diwan S; Kehn M; Ramirez PM
Am J Geriatr Psychiatry; 2007 Dec; 15(12):1015-23. PubMed ID: 18056820
[TBL] [Abstract][Full Text] [Related]
39. Prospective study of men's psychological and decision-related adjustment after treatment for localized prostate cancer.
Steginga SK; Occhipinti S; Gardiner RA; Yaxley J; Heathcote P
Urology; 2004 Apr; 63(4):751-6. PubMed ID: 15072894
[TBL] [Abstract][Full Text] [Related]
40. Decision analyses in consideration of treatment strategies for patients with biochemical failure after curative therapy on clinically localized prostate cancer in the prostate-specific antigen era.
Shimizu F; Igarashi A; Fukuda T; Kawachi Y; Minowada S; Ohashi Y; Fujime M
Jpn J Clin Oncol; 2007 Oct; 37(10):763-74. PubMed ID: 17956899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
